Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
Mubritinib
Другие языки:

    Mubritinib

    Подписчиков: 0, рейтинг: 0
    Mubritinib
    Mubritinib.svg
    Clinical data
    Routes of
    administration    		 Oral
    ATC code
    • none
    Legal status
    Legal status
    • In general: uncontrolled
    Identifiers
    • 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole
    CAS Number
    PubChem CID
    IUPHAR/BPS
    ChemSpider
    UNII
    ChEMBL
    Chemical and physical data
    Formula C25H23F3N4O2
    Molar mass 468.480 g·mol−1
    3D model (JSmol)
    • FC(F)(F)c1ccc(cc1)\C=C\c2nc(co2)COc3ccc(cc3)CCCCn4nncc4
    • InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
    • Key:ZTFBIUXIQYRUNT-MDWZMJQESA-N

    Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.

    See also



    Новое сообщение